|0.3266|| -0.0334 / -9.28%|
Taxus Cardium Pharmaceuticals Group, Inc. is an is an advanced regenerative therapeutics company, which focuses on the late-stage clinical and commercial development of regenerative medicine therapeutics including Generx an interventional cardiology angiogenic gene therapy product candidate designed for the treatment of Cardiac Microvascular Insufficiency due to advancing coronary artery disease, and Excellagen, an FDA-cleared acellular biological skin substitute designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has multiple additional potential tissue regeneration applications based on stem cells and other biologics. The company was founded by Christopher J. Reinhard and Tyler M. Dylan-Hyde on December 22, 2003 and is headquartered in San Diego, CA.
|Christopher J. Reinhard||Chairman, President, CEO, CFO, Treasurer & CAO|
|Ted Williams||VP-Manufacturing & Technical Operations|
|Gabor M. Rubanyi||Chief Scientific Officer|
|Lois A. Chandler||Vice President-Biologics Development|
|Duane M. Linstrom||Secretary|